# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues...
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspec...
Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.
Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $1...